Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

7.7%

5 terminated/withdrawn out of 65 trials

Success Rate

90.6%

+4.1% vs industry average

Late-Stage Pipeline

35%

23 trials in Phase 3/4

Results Transparency

4%

2 of 48 completed trials have results

Key Signals

6 recruiting2 with results

Enrollment Performance

Analytics

Phase 3
22(37.9%)
Phase 2
15(25.9%)
N/A
14(24.1%)
Phase 1
5(8.6%)
Phase 4
1(1.7%)
Early Phase 1
1(1.7%)
58Total
Phase 3(22)
Phase 2(15)
N/A(14)
Phase 1(5)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (65)

Showing 20 of 65 trials
NCT06421675Phase 2Recruiting

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

Role: lead

NCT05417516Phase 3Recruiting

A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)

Role: lead

NCT06654336Phase 2Recruiting

Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)

Role: lead

NCT03250247Not ApplicableActive Not Recruiting

Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)

Role: collaborator

NCT05866458Recruiting

Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy

Role: lead

NCT04228991Phase 3Active Not Recruiting

Hypofractionated LocoRegional Radiotherapy in Breast Cancer

Role: lead

NCT04797299Recruiting

Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ (DCIS)

Role: lead

NCT04090710Phase 2Active Not Recruiting

SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer

Role: lead

NCT01791829Active Not Recruiting

A Prospective Cohort Study Evaluating Risk of Local Recurrence Following Breast Conserving Surgery and Endocrine Therapy in Low Risk Luminal A Breast Cancer

Role: lead

NCT05137899Phase 2Terminated

Neoadjuvant Combination of Atezolizumab/Bevacizumab Versus Neoadjuvant Radiation Therapy

Role: lead

NCT02462239Not ApplicableCompleted

Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging

Role: lead

NCT06126614Phase 3Recruiting

Infection Prophylaxis in Total Joint Replacement

Role: collaborator

NCT00310232Phase 3Terminated

Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)

Role: lead

NCT02751710Not ApplicableCompleted

Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer

Role: lead

NCT02637024Phase 2Completed

Trial of Radiation Fractionation Schedules for Once-a-Day Accelerated Partial Breast Irradiation

Role: lead

NCT01968941Phase 3Completed

Stereotactic Body Radiotherapy Versus Conventional Radiotherapy in Medically-Inoperable Non-Small Lung Cancer Patients

Role: lead

NCT02813226Not ApplicableCompleted

Assessment of New Molecular Imaging Strategies for Prostate Cancer

Role: lead

NCT02076672Phase 2Completed

Investigation of the Anti-Cancer Activity of Artichoke Extract in an Asbestos-Exposed Population

Role: lead

NCT03333785Not ApplicableCompleted

Randomized Trial of eOncoNote

Role: collaborator

NCT02485678Not ApplicableCompleted

A Pragmatic Trial of Ambulatory Toxicity Management in Patients Receiving Adjuvant or Neo-adjuvant Chemotherapy for Early Stage Breast Cancer

Role: lead